secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0000320017-25-000063
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata grants Catalent non-exclusive license for certepetide ADC payload; up to $10.5M milestones
--------------------------------------------------------------------------------

- Granted Catalent non-exclusive license to use certepetide as ADC payload in SMARTag platform; Catalent assumes all R&D/commercial costs.
- Eligible for up to $10.5M in development milestone payments plus tiered revenue sharing on future sales/partnerships.
- Also entitled to portion of sublicense consideration received by Catalent.
- Catalent may terminate agreement on 30 days notice; also grants Lisata ROFN for out-licensing of resulting assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000063/0000320017-25-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000063/clbs-20251008.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer